Merck KGaA Looks To Chinese Medicine For Oncology Candidates
This article was originally published in The Pink Sheet Daily
Collaboration with China’s Chi-Med is part of an initiative to strengthen Merck’s natural compound expertise, exec tells “The Pink Sheet” DAILY.
You may also be interested in...
BEIJING - Shanghai-headquartered Hutchison MediPharma signed a new partnership agreement with Eli Lilly on drug discovery and development, according to MediPharma's chief executive officer
Chi-Med's wholly owned research and development subsidiary Hutchison MediPharma will collaborate with Eli Lilly on the discovery and development of pharmaceutical targets in oncology and inflammation, Chi-Med announced Aug. 20
Deal could be worth $29 million per candidate, Chi-Med CEO tells “The Pink Sheet” DAILY.